Atossa Genetics (ATOS)
(Delayed Data from NSDQ)
$1.46 USD
0.00 (0.00%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.46 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth B Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ATOS 1.46 0.00(0.00%)
Will ATOS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ATOS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ATOS
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?
Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year?
ATOS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are You Looking for a Top Momentum Pick? Why Atossa Genetics Inc. (ATOS) is a Great Choice
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?
Are Medical Stocks Lagging Alvotech (ALVO) This Year?
Other News for ATOS
Atossa Therapeutics announces support of final rule from FDA
Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer
Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
Atossa Therapeutics Granted Additional Patent Protection for Endoxifen
Atossa Therapeutics granted U.S. patent for endoxifen